Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

By Teresa Palomero, M. Sulis, Maria Cortina, P. Real, Kelly Barnes, M. Ciofani, E. Caparrós, J. Buteau, K. Brown, S. Perkins and 10 more. Nature Medicine, 2007

911 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a3ac2d1dc553559eb464ec28c0c3f0e876e9ffd1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. P. Pandolfi
2. Arkaitz Carracedo
3. L. Salmena
4. S. Pounds
5. P. Dirks
6. Bradley Efron
7. T. Balla

Citations in the corpus

• Tenets of PTEN tumor suppression. (2008, background): “through the HES-1 transcription factor (Palomero et al., 2007).”
• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011, background): “Although many groups have investigated the PTEN-phosphorylation status in leukemia and lymphoma, its relevance concerning Akt-activation is still not clear [129-133].”
• THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (2017, positive): “Several intracellular signaling pathways are activated by mutation, including the PI3K–AKT–mTOR pathway, most commonly affected by PTEN deletion 18,32 , PTPN2 deletion 33 or AKT1 mutation 34 ; the JAK–STAT pathway via activating mutations in the interleukin 7 receptor α -chain gene ( IL7R ) 35,36 ,…”
• Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “For example, NOTCH1 regulates the PTEN –phosphoinositide 3-kinase (PI3K)– AKT pathway in T cell acute lymphoblastic leukaemia (T-ALL”
• The PTEN–PI3K pathway: of feedbacks and cross-talks (2008, background): “Indeed, in T-cell acute lymphoblastic leukemia, aberrant Notch pathway represses PTEN transcription through induction of HES-1 in turn providing a novel therapeutic approach for the treatment of this malignancy with the combined inhibition of PI3K and Notch pathways (Palomero et al., 2007).”